Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Hitting the Target but Missing the Point: Recent Progress Towards Adenovirus-Based Precision Virotherapies

Version 1 : Received: 4 October 2020 / Approved: 5 October 2020 / Online: 5 October 2020 (12:21:00 CEST)

How to cite: Cunliffe, T.G.; Bates, E.A.; Parker, A.L. Hitting the Target but Missing the Point: Recent Progress Towards Adenovirus-Based Precision Virotherapies. Preprints 2020, 2020100084 (doi: 10.20944/preprints202010.0084.v1). Cunliffe, T.G.; Bates, E.A.; Parker, A.L. Hitting the Target but Missing the Point: Recent Progress Towards Adenovirus-Based Precision Virotherapies. Preprints 2020, 2020100084 (doi: 10.20944/preprints202010.0084.v1).

Abstract

More people are surviving longer with cancer. Whilst this can be partially attributed to advances in early detection of cancers, there is little doubt that the improvement in survival statistics is also due to the expansion in the spectrum of treatments available for efficacious treatment. Transformative amongst those are immunotherapies, which have proven effective agents for treating immunogenic forms of cancer, though immunologically “cold” tumour types remain refractive. Oncolytic viruses, such as those based on adenovirus have great potential as anti-cancer agents and have seen a resurgence of interest in recent years. Amongst their many advantages is their ability to induce immunogenic cell death (ICD) of infected tumour cells, thus providing the alluring potential to synergize with immunotherapies by turning immunologically “cold” tumours “hot”. Additionally, enhanced immune mediated cell killing can be promoted through the local overexpression of immunological transgenes, encoded from within the engineered viral genome. To achieve this full potential requires the development of refined, tumour selective “precision virotherapies” that are extensively engineered to prevent off-target up take via native routes of infection, and targeted to infect and replicate uniquely within malignantly transformed cells. Here, we review the latest advances towards this holy grail within the adenoviral field.

Subject Areas

adenovirus; oncolytic; virotherapy; targeting; immunotherapy; immunogenic cell death; αvβ6 integrin

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.